A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490).
about
Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 studyTimed sequential chemotherapy with concomitant granulocyte colony-stimulating factor for high-risk acute myelogenous leukemia: a single arm clinical trialG-CSF and GM-CSF in NeutropeniaInvasive mold infections in solid organ transplant recipientsCombination of IFN-α/Gm-CSF as a Maintenance Therapy for Multiple Myeloma Patients After Autologous Stem Cell Transplantation (ASCT): A Prospective Phase II Study.A phase I study using bortezomib with weekly idarubicin for treatment of elderly patients with acute myeloid leukemia.Granulocyte colony-stimulating factor and azole antifungal therapy in murine aspergillosis: role of immune suppressionThe number of CD34+CD38+CD117+HLA-DR+CD13+CD33+ cells indicates post-chemotherapy hematopoietic recovery in patients with acute myeloid leukemia.Effects of cytokines and fluconazole on the activity of human monocytes against Candida albicans.Short communication: Activating stimuli enhance immunotoxin-mediated killing of HIV-infected macrophages.Anthracycline dose intensification in acute myeloid leukemia.Mesenchymal stem cell therapy for acute radiation syndrome: innovative medical approaches in military medicineThe association of transporter genes polymorphisms and lung cancer chemotherapy responseEffects of granulocyte and granulocyte-macrophage colony-stimulating factors in a neutropenic murine model of trichosporonosis.A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemiaSequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222.Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome.Exogenous endothelial cells as accelerators of hematopoietic reconstitution.Adult patients with acute myeloid leukemia who achieve complete remission after 1 or 2 cycles of induction have a similar prognosis: a report on 1980 patients registered to 6 studies conducted by the Eastern Cooperative Oncology Group.Granulocyte macrophage colony-stimulating factor in 66 patients with myeloid or lymphoid neoplasms and recipients of hematopoietic stem cell transplantation with invasive fungal disease.Clinical management of primary non-acute promyelocytic leukemia acute myeloid leukemia: Practice Guidelines by the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation.Independent Prognostic Significance of Monosomy 17 and Impact of Karyotype Complexity in Monosomal Karyotype/Complex Karyotype Acute Myeloid Leukemia: Results from Four ECOG-ACRIN Prospective Therapeutic Trials.Single infusion of myeloid progenitors reduces death from Aspergillus fumigatus following chemotherapy-induced neutropenia.Extramedullary Disease in Adult Acute Myeloid Leukemia Is Common but Lacks Independent Significance: Analysis of Patients in ECOG-ACRIN Cancer Research Group Trials, 1980-2008.Clinical uses of GM-CSF, a critical appraisal and update.Modulating host immune responses to fight invasive fungal infections.
P2860
Q24670020-D8888321-F8B6-468E-A92B-DD1C4176B02AQ24792014-A31FF6B3-149E-487A-85C0-20B5AEEF35C4Q26800954-49CDE5F7-4BC6-46DC-9EE7-B5B0A7CBAD68Q26823811-401B83B5-92FE-464D-B20F-8FF0F2365E5FQ33393257-8CBFAC90-EC13-4642-B7FA-C72AB1063D45Q33630851-BD0AA96D-D7BF-49CA-9E65-3B7751F9D963Q33697679-E0CE98C9-39F6-4721-B4E4-38DD5FAB558FQ33874174-6FBD6F06-5693-4C69-A9F8-7BD5FC409D8DQ33981130-A5EA355A-5A4D-44BE-9824-D9FEBE292C6DQ34085094-76258CBF-DCC9-4A68-8A74-108B501D7D58Q34612121-3892C4A1-50BF-4905-A965-4A5ABF06DF26Q35122122-A659500A-52E8-440F-8C7B-EC769CF841AEQ35124361-438AD69B-175A-454A-BBE6-BC6F6B4AF5B5Q35553643-DEB71D0D-0582-49A3-AC33-F4415AB27D9AQ35628954-D9C9E7BE-5902-4D14-BA21-9F0A6FA63261Q35847482-0C09AA6C-EEE2-423C-97E4-44D65F6AC21BQ35984641-4E773318-9FAB-4A0E-ACD3-C12A5F630C85Q36527110-92F5A653-4ECB-4850-A154-038BE8BF5095Q36593525-4FD11E53-8C68-4D01-9D0D-D00BEAED5BF2Q36755190-6F457741-57EE-4764-A265-79D56AE0410AQ37323006-5C7D086D-EB6F-4E68-AEDE-470D510172AEQ38760193-A0D1ECED-CACD-4F07-9354-156123E97D27Q41962909-87B8B2AB-F24B-4D33-B7B2-EF2BFB66B7E6Q42381012-BD9ECA47-19EF-4CDB-9347-6CA29970D47DQ43068695-7CCB7593-5AA2-4BE2-8FE9-3980F7A37FE4Q46673081-9D79F477-3371-4E77-BCCB-DEF0AEA316AB
P2860
A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490).
description
1995 nî lūn-bûn
@nan
1995 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
A randomized placebo-controlle ...... rative Oncology Group (E1490).
@ast
A randomized placebo-controlle ...... rative Oncology Group (E1490).
@en
A randomized placebo-controlle ...... ating factor in adult patients
@nl
type
label
A randomized placebo-controlle ...... rative Oncology Group (E1490).
@ast
A randomized placebo-controlle ...... rative Oncology Group (E1490).
@en
A randomized placebo-controlle ...... ating factor in adult patients
@nl
prefLabel
A randomized placebo-controlle ...... rative Oncology Group (E1490).
@ast
A randomized placebo-controlle ...... rative Oncology Group (E1490).
@en
A randomized placebo-controlle ...... ating factor in adult patients
@nl
P2093
P921
P1433
P1476
A randomized placebo-controlle ...... erative Oncology Group (E1490)
@en
P2093
Andersen JW
Bennett JM
Cassileth PA
Stadtmauer EA
Wiernik PH
P304
P407
P577
1995-07-01T00:00:00Z